Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005623 · ClinicalTrials.gov registry record · Phase 3
Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer
A Phase 3 study of Prostate Cancer and Hot Flashes, sponsored by Barr Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 1
- Study location
NCT00005623 is a Phase 3 study of Prostate Cancer and Hot Flashes that has completed, run by Barr Laboratories. The trial reports 1 study location across 1 state.
The verdict
NCT00005623, a Phase 3 study of Prostate Cancer and Hot Flashes, has completed, sponsored by Barr Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Cyproterone acetate may be effective treatment for hot flashes following surgical or chemical castration for prostate cancer. It is not yet known which regimen of cyproterone acetate is more effective for hot flashes. PURPOSE: Randomized phase III trial to determine the effectiveness of cyproterone acetate in treating patients who have hot flashes following surgical or chemical castration for prostate cancer.
Conditions Studied
Interventions
- PROCEDURE quality-of-life assessment
- DRUG cyproterone acetate
Study Locations (1)
New York
- Barr Laboratories, Incorporated - Pomona
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-12 |
| Est. Completion | 2004-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005623
The ClinicalTrials.gov registry entry for NCT00005623 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Barr Laboratories, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT00005623 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00005623 about?
NCT00005623 is a clinical study titled "Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer". RATIONALE: Cyproterone acetate may be effective treatment for hot flashes following surgical or chemical castration for prostate cancer. It is not yet known which regimen of cyproterone acetate is more effective for hot flashes. PURPOSE: Randomized phase III trial to determine the effectiveness of ...
What is the current status of trial NCT00005623?
This trial is currently completed. It is a Phase 3 study. The study started on 1999-12. Estimated completion is 2004-01.
What conditions does trial NCT00005623 study?
This clinical trial studies the following conditions: Prostate Cancer, Hot Flashes.
What interventions are being tested in trial NCT00005623?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), cyproterone acetate (DRUG).
Who is sponsoring clinical trial NCT00005623?
This trial is sponsored by Barr Laboratories, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005623 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.